PMID- 34237826
OWN - NLM
STAT- MEDLINE
DCOM- 20210719
LR  - 20210910
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Print)
IS  - 1226-3303 (Linking)
VI  - 36
IP  - 4
DP  - 2021 Jul
TI  - Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for 
      Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic 
      asthma.
PG  - 1001-1013
LID - 10.3904/kjim.2020.549 [doi]
AB  - BACKGROUND/AIMS: Omalizumab is the first biologic known to be effective in 
      patients with severe allergic asthma. METHODS: This study was conducted as a 
      multicenter, single-group, open trial to evaluate the improvement in the quality 
      of life with the additional administration of omalizumab for 24 weeks in Korean 
      patients with severe persistent allergic asthma. RESULTS: Of the 44 patients, 
      31.8% were men and the mean age was 49.8 +/- 11.8 years. A score improvement of 0.5 
      points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) 
      was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline 
      total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, 
      and the day and night asthma symptoms were more severe, compared to those in the 
      non-improved group. According to the Global Evaluation of Treatment 
      Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean 
      asthma control test (p < 0.005) and forced expiratory volume in 1 second % 
      predicted (FEV1%; p < 0.01) improved significantly in patients who received 
      omalizumab treatment, compared to that at week 0, and the total dose of rescue 
      systemic corticosteroids significantly decreased (p < 0.05). The improved group 
      on KAQLQ showed a significant improvement in FEV1% (p < 0.001). CONCLUSION: 
      Omalizumab can be considered a biological treatment for Korean patients with 
      severe allergic asthma. It is recommended to consider omalizumab as add-on 
      therapy in patients with high baseline total IgE levels and severe asthma 
      symptoms.
FAU - Jung, Jae-Woo
AU  - Jung JW
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
FAU - Park, Hae-Sim
AU  - Park HS
AD  - Department of Allergy and Clinical Immunology, Ajou University School of 
      Medicine, Suwon, Korea.
FAU - Park, Choon-Sik
AU  - Park CS
AD  - Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 
      Bucheon, Korea.
FAU - Cho, Sang-Heon
AU  - Cho SH
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Choi, Inseon S
AU  - Choi IS
AD  - Department of Internal Medicine, Chonnam National University Hospital, Gwangju, 
      Korea.
FAU - Moon, Hee-Bom
AU  - Moon HB
AD  - Department of Allergy and Clinical Immunology, Asan Medical Center, University of 
      Ulsan College of Medicine, Seoul, Korea.
FAU - Kwon, Soon Seog
AU  - Kwon SS
AD  - Department of Internal Medicine, Bucheon St. Mary's Hospital, College of 
      Medicine, The Catholic University of Korea, Bucheon, Korea.
FAU - Yoon, Ho Joo
AU  - Yoon HJ
AD  - Department of Internal Medicine, Hanyang University College of Medicine, Seoul, 
      Korea.
FAU - Park, Jung Won
AU  - Park JW
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Lee, Jong-Myung
AU  - Lee JM
AD  - Department of Internal Medicine, School of Medicine, Kyungpook National 
      University, Daegu, Korea.
FAU - Choi, Dong-Chull
AU  - Choi DC
AD  - Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
FAU - Choi, Byoung Whui
AU  - Choi BW
AD  - Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, 
      Korea.
AD  - Department of Internal Medicine, Chung-Ang University H.C.S. Hyundae Hospital, 
      Namyangju, Korea.
LA  - eng
GR  - Novartis Pharmaceuticals Corporation/
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210601
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
EIN - Korean J Intern Med. 2021 Sep;36(5):1260. PMID: 34503321
MH  - Adult
MH  - *Anti-Asthmatic Agents/adverse effects
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - *Asthma/diagnosis/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omalizumab/adverse effects
MH  - Quality of Life
MH  - Republic of Korea
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC8273830
OTO - NOTNLM
OT  - Asthma
OT  - Omalizumab
OT  - Prospective studies
OT  - Quality of life
OT  - Republic of Korea
COIS- This study was supported by Novartis Pharmaceuticals.
EDAT- 2021/07/09 06:00
MHDA- 2021/07/20 06:00
PMCR- 2021/07/01
CRDT- 2021/07/08 22:33
PHST- 2020/10/08 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/07/08 22:33 [entrez]
PHST- 2021/07/09 06:00 [pubmed]
PHST- 2021/07/20 06:00 [medline]
PHST- 2021/07/01 00:00 [pmc-release]
AID - kjim.2020.549 [pii]
AID - kjim-2020-549 [pii]
AID - 10.3904/kjim.2020.549 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2021 Jul;36(4):1001-1013. doi: 10.3904/kjim.2020.549. Epub 
      2021 Jun 1.